Vasomotor Symptoms Market Trends and Competitive Analysis By 2027

Market Highlights

According to MRFR analysis, the Global Vasomotor Symptoms Market is expected to register a CAGR of 7.27% from 2020 to 2027 and hold a value of USD 8,189 Million till 2027.

The global vasomotor symptoms market is driven by several factors, such as rising older female population, rising initiatives by public and private organizations to create awareness regarding vasomotor symptoms management options, increasing product launches, and a number of clinical trials by the prominent players in the market. The increasing menopausal women also contribute heavily to the growth of this market. By 2030, the world population of menopausal and postmenopausal women is projected to increase to 1.2 billion, with 47 million new entrants each year.

A lot of market players are dominating the global vasomotor symptoms market. The prominent players are involved in strategic agreements, product launches, and joint ventures to sustain their market positions. For instance, in October 2018, TherapeuticsMD (US) received FDA approval for its first bioidentical hormone therapy BIJUVA, a combination of estradiol and progesterone for moderate to severe vasomotor symptoms associated with menopause

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas held the maximum share in 2019, owing to the rise in menopausal women in the US. For instance, in the US, approximately 1.3 million women become menopausal each year. The vasomotor symptoms market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European vasomotor symptoms market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The European market for vasomotor symptoms is expected to hold a substantial share owing to the increase in the number of clinical trials by the prominent players. The vasomotor symptoms market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The vasomotor symptoms market in this region is anticipated to be the fastest-growing during the forecast period due to the increasing uptake and adoption rate of hormonal therapy. Increasing patient pool also fuels the market growth. The vasomotor symptoms market in the Middle East & Africa has been divided into the Middle East and Africa.


Global Vasomotor Symptoms Market has been segmented based on the Therapy Type and Distribution Channel.

The market, based on therapy type, has been segmented into hormonal and non-hormonal. The market, based on hormonal therapy, has been further divided into estrogen, progesterone, and combination. The market, based on hormonal therapy, held a major share in 2019 owing to the widespread use and high preference rate. The market, based on non-hormonal therapy, has been further divided into antidepressants and others.

The global vasomotor symptoms market has been segmented, based on distribution channel, into hospital pharmacies, online stores, and retail pharmacies. The hospital pharmacies segment held the majority share of the market in 2019 owing to the increasing number of in-visit patient admissions, whereas the online stores segment is projected to be the fastest-growing segment during the study period owing to the increasing preference of this distribution channels owing to the widespread availability and rise in awareness regarding the e-commerce channels.

Key Players

Some of the key players in the global vasomotor symptoms market are Allergan (Ireland), Pfizer Inc. (US), Eli Lily and Company (US), Novartis AG (Switzerland), Emcure Pharmaceuticals Ltd (India), Merck & Co., Inc. (US), TherapeuticsMD, Inc. (US), Mithra Pharmaceuticals (Belgium), Novo Nordisk A/S (Denmark), Procter & Gamble (US), EndoCeutics, Inc. (Canada), Amag Pharmaceuticals (US), and Teva Pharmaceuticals (Israel).